Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05438160 · ClinicalTrials.gov registry record · NA
Exploratory Study of a Digital Therapeutics in People With Schizophrenia
A NA study of Schizophrenia, sponsored by Click Therapeutics.
- Completed
- Registry status
- NA
- Development phase
- 48
- Enrollment target
- 7
- Study locations
NCT05438160 is a NA study of Schizophrenia that has completed, run by Click Therapeutics. The registered enrollment target is 48 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (78% lower). The trial reports 7 study locations across 3 states.
The verdict
NCT05438160, a NA study of Schizophrenia, has completed, sponsored by Click Therapeutics.
- COMPLETED
- Registry status
- NA
- Development phase
- 48 participants
- Enrollment target
- 7
- Study locations
Study Summary
CT-155 is a novel prescription digital therapeutic (PDT) being developed by Click Therapeutics, Inc. (Click) and Boehringer Ingelheim (BI) using an interactive, software-based intervention to treat schizophrenia
Conditions Studied
Interventions
- DEVICE Clinical Learning Study smartphone app (i.e., the study app)
Study Locations (7)
Florida
- CT-155 Center - Hialeah
- CT-155 Center - Lake Mary
- CT-155 Center - Miami
California
- CT-155 Center - Anaheim
- CT-155 Center - Torrance
Texas
- CT-155 Center - Irving
- CT-155 Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2022-03-31 |
| Est. Completion | 2022-07-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05438160
The ClinicalTrials.gov registry entry for NCT05438160 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (78% lower). The listed sponsor is Click Therapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Clinical Learning Study smartphone app (i.e., the study app) is the first listed.
NCT05438160 reports 7 study locations spanning 3 distinct geographic areas - top geographies include Florida, California, Texas.
Frequently Asked Questions
What is clinical trial NCT05438160 about?
NCT05438160 is a clinical study titled "Exploratory Study of a Digital Therapeutics in People With Schizophrenia". CT-155 is a novel prescription digital therapeutic (PDT) being developed by Click Therapeutics, Inc. (Click) and Boehringer Ingelheim (BI) using an interactive, software-based intervention to treat schizophrenia
What is the current status of trial NCT05438160?
This trial is currently completed. It is a NA study. The enrollment target is 48 participants. The study started on 2022-03-31. Estimated completion is 2022-07-31.
What conditions does trial NCT05438160 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT05438160?
The interventions under investigation include: Clinical Learning Study smartphone app (i.e., the study app) (DEVICE).
Who is sponsoring clinical trial NCT05438160?
This trial is sponsored by Click Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05438160 being conducted?
This trial has 7 study locations across California, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Taking Action for College Students
RECRUITING · NA
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
RECRUITING · NA
-
Cerebellar Modulation of Cognition in Psychosis
RECRUITING · NA
-
TMS for Inhibition Enhancement in Schizophrenia
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.